⌘K
Loading ticker…
NewAmsterdam Pharma Company N.V. Ordinary Shares · Healthcare · Pharmaceutical Products
As of 2026-06-26, NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a 3-month relative strength percentile of 52 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 56. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.4%, relative volume 1.18×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
52 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
NAMS appears in 1 ETF as of Feb 2026: AVUS at 0.00% weight, $10K notional.
Top 1 by value, from SEC N-PORT-P filings dated Feb 2026.
| ETF | Weight | Value |
|---|---|---|
| AVUSAvantis U.S. Equity ETF | 0.00% | $10K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NAMS Jan avg: 20.35% median: 5.71% win: 50% σ: 45.07% n: 4 2022-11-25 → 2026-05-29 | NAMS Feb avg: 4.61% median: 5.13% win: 50% σ: 9.64% n: 4 2022-11-25 → 2026-05-29 | NAMS Mar avg: -2.06% median: -1.03% win: 50% σ: 5.68% n: 4 2022-11-25 → 2026-05-29 | NAMS Apr avg: -4.45% median: -7.16% win: 25% σ: 8.04% n: 4 2022-11-25 → 2026-05-29 | NAMS May avg: -1.01% median: -3.97% win: 25% σ: 13.53% n: 4 2022-11-25 → 2026-05-29 | NAMS Jun avg: -3.92% median: 0.00% win: 33% σ: 9.00% n: 3 2022-11-25 → 2026-05-29 (current) | NAMS Jul avg: 2.15% median: -3.11% win: 33% σ: 16.30% n: 3 2022-11-25 → 2026-05-29 | NAMS Aug avg: -1.44% median: -4.09% win: 33% σ: 10.64% n: 3 2022-11-25 → 2026-05-29 | NAMS Sep avg: 3.02% median: 1.10% win: 67% σ: 14.37% n: 3 2022-11-25 → 2026-05-29 | NAMS Oct avg: 11.09% median: 2.53% win: 67% σ: 19.53% n: 3 2022-11-25 → 2026-05-29 | NAMS Nov avg: 3.04% median: 8.64% win: 75% σ: 16.94% n: 4 2022-11-25 → 2026-05-29 | NAMS Dec avg: 15.86% median: 21.96% win: 75% σ: 22.31% n: 4 2022-11-25 → 2026-05-29 |